Biogen Inc. has entered into a definitive agreement to acquire Apellis Pharmaceuticals via a tender offer at $41.00 per share in cash, plus a contingent value right (CVR) worth up to an additional $4.00 per share. The total potential consideration of $45.00 per share is tied to specific future sales milestones for the product SYFOVRE. This transaction represents a significant strategic acquisition aimed at expanding Biogen's commercial portfolio and market presence.
